IDEAYA Biosciences (IDYA) Accumulated Expenses (2018 - 2026)

IDEAYA Biosciences has reported Accumulated Expenses for 9 years, with the latest figure at $43.7 million in Q1 2026.

• Quarterly Accumulated Expenses rose 32.94% year-over-year to $43.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.7 million (up 32.94% YoY) and the FY2025 annual result came in at $11.2 million, down 63.11% from the prior year.
• Accumulated Expenses rose to $43.7 million in Q1 2026 per IDYA's latest filing, from $11.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $45.3 million in Q3 2025 and troughed at $2.6 million in Q1 2022.
• A 5-year average of $17.7 million and a median of $14.7 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses slumped 65.99% in 2022, then soared 598.17% in 2025.
• Over 5 years, Accumulated Expenses stood at $5.2 million in 2022, then soared by 32.89% to $7.0 million in 2023, then soared by 335.22% to $30.4 million in 2024, then sank by 63.11% to $11.2 million in 2025, then surged by 290.65% to $43.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $43.7 million, $11.2 million, and $45.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.